Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …

Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …

Background In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …

Background GLOW is a phase 3 trial evaluating the efficacy and safety of ibrutinib-
venetoclax in older patients and/or those with comorbidities with previously untreated …

Background Zanubrutinib is a next-generation, selective Bruton tyrosine kinase inhibitor with
efficacy in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma …

PURPOSE Acalabrutinib, a highly selective, potent, Bruton tyrosine kinase inhibitor, was
evaluated in this global, multicenter, randomized, open-label, phase III study in patients with …

Background Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …

Background Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown
superior efficacy to chlorambucil monotherapy and are standard first-line treatments in …

Ibrutinib, a once‐daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United
States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small …

Background Deletion of chromosome 17p (del [17p]) in patients with chronic lymphocytic
leukaemia confers very poor prognosis when treated with standard chemo-immunotherapy …